InvestSMART

Neurotech International Limited (ASX: NTI) - Announcements

Current share price for NTI : $0.015 0.001 (3.57%)+

ASX company news and announcements for Neurotech International Limited (NTI) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurotech International Limited (NTI) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurotech International Limited (NTI), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurotech International Limited (NTI)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$23 Investor Presentation 8 Jul 2022 1:11PM $0.079 $0.015 fallen by 81.65%
$23 Investor Webinar 8 Jul 2022 11:04AM $0.073 $0.015 fallen by 80.14%
$23 Reinstatement to Official Quotation 8 Jul 2022 9:33AM $0.075 $0.015 fallen by 80.67%
$23 BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD 8 Jul 2022 9:33AM $0.075 $0.015 fallen by 80.67%
$23 Extension to Voluntary Suspension 7 Jul 2022 10:02AM $0.075 $0.015 fallen by 80.67%
$23 Suspension from Official Quotation 6 Jul 2022 9:49AM $0.075 $0.015 fallen by 80.67%
$23 Trading Halt 4 Jul 2022 9:33AM $0.075 $0.015 fallen by 80.67%
$23 Neurotech CEO to Present at Gold Coast Investment Showcase 22 Jun 2022 10:40AM $0.057 $0.015 fallen by 74.56%
$23 Proposed issue of securities - NTI 9 Jun 2022 11:13AM $0.069 $0.015 fallen by 78.99%
$23 Preclinical Success with Targeted Combination Therapies 9 Jun 2022 10:56AM $0.064 $0.015 fallen by 77.34%
$23 Investor Webinar Presentation 3 Jun 2022 8:37AM $0.059 $0.015 fallen by 75.42%
$23 Neurotech CEO to Present at Bioshares Conference 12 May 2022 9:55AM $0.050 $0.015 fallen by 71%
$23 Key Development in Current Paediatric ASD Study 12 May 2022 9:32AM $0.050 $0.015 fallen by 71%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2022 9:01AM $0.049 $0.015 fallen by 70.41%
$23 Q&A With Company CEO, Dr Alex Andrews 13 Apr 2022 8:42AM $0.057 $0.015 fallen by 74.56%
$23 Successful Landmark Study in Paediatric ASD 5 Apr 2022 9:32AM $0.059 $0.015 fallen by 75.42%
$23 Notification regarding unquoted securities - NTI 10 Mar 2022 8:13PM $0.047 $0.015 fallen by 69.15%
$23 Medicinal Cannabis Presentation 10 Mar 2022 8:58AM $0.047 $0.015 fallen by 69.15%
$23 Proposed issue of securities - NTI 3 Mar 2022 6:21PM $0.044 $0.015 fallen by 67.05%
$23 Appointment of Chief Executive Officer 3 Mar 2022 9:11AM $0.045 $0.015 fallen by 67.78%
$23 Appendix 4D and Half Year Accounts 24 Feb 2022 6:28PM $0.047 $0.015 fallen by 69.15%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2022 9:56AM $0.051 $0.015 fallen by 71.57%
$23 Application for quotation of securities - NTI 24 Jan 2022 6:49PM $0.051 $0.015 fallen by 71.57%
$23 Change of Registry Address 20 Dec 2021 2:56PM $0.056 $0.015 fallen by 74.11%
$23 Change of Director's Interest Notice x 2 13 Dec 2021 8:00PM $0.058 $0.015 fallen by 75%

326 - 350 of 694 results

Page 14 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.